Welcome to our dedicated page for INTUITIVE SURGICAL SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical director Gary S. Guthart reported an option exercise and related share sales. On January 27, 2026, a non-qualified stock option for 25,500 shares was exercised at $174.2567 per share, increasing his directly held common stock to 28,194 shares.
That same day, 24,500 common shares held directly were sold at a weighted average price of $530.0981, leaving 3,694 directly held shares. In addition, 1,400 shares were sold from a trust for his daughter and 1,400 shares from a trust for his son, each at weighted average prices just above $531, with 15,720 shares remaining in each child’s trust and 1,231,890 shares indirectly held by a separate trust. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan that expires on April 28, 2026.
A planned insider sale has been filed for ISRG common stock under Rule 144. The notice covers the proposed sale of 24,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $12,987,403.45 at the time of filing.
The shares to be sold were acquired on 01/27/2026 via a stock option exercise, paid in cash, involving the same 24,500 shares. The filing also shows that Gary S. Guthart sold 22,806 common shares on 12/01/2025 for $13,019,721.90 in gross proceeds during the prior three months.
A shareholder of ISRG has filed a notice of proposed sale under Rule 144 to sell 230 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares to be sold have an aggregate market value of $122,500.30, while 354,496,073 shares of the issuer’s common stock are reported as outstanding. The planned sale date is listed as 01/27/2026 on the NASDAQ market, and the shares were acquired on the same date via a stock option exercise paid in cash.
The filer also reports prior sales of the issuer’s common stock during the past three months, including a transaction on 10/28/2025 in which 7,562 shares were sold for $4,147,192.12 in gross proceeds. By signing, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.
A shareholder has filed a Form 144 indicating an intention to sell up to 2,800 shares of common stock through The Charles Schwab Corporation on the NASDAQ, with an aggregate market value of 1,488,269.00. The filing lists 354,496,073 shares of this class as outstanding, providing context for the planned sale. The shares to be sold were acquired on 12/03/2018 via a stock option exercise from the issuer, with payment made on the same date.
Intuitive Surgical, Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1, giving investors access to the company’s quarterly performance details outside this report.
The company notes that the information contained in the report, including Exhibit 99.1, is being furnished rather than filed, meaning it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC filings. The report is signed on behalf of Intuitive by its Executive Vice President and Chief Financial Officer, Jamie E. Samath.
Intuitive Surgical, Inc. furnished a report stating that it has issued a press release with unaudited preliminary financial results for the fourth quarter and full year 2025. The release is provided as Exhibit 99.1.
The company also supplied additional unaudited preliminary revenue and procedure information in tabular form as Exhibit 99.2, which has been posted to the Investor Relations section of its website. The materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Intuitive Surgical, Inc. reported a leadership role change in its digital organization. Effective January 1, 2026, Brian E. Miller, Ph.D., will move from his current position as Chief Digital Officer to become Head of Digital and AI Strategy. In this new role, Dr. Miller will continue focusing on the company’s digital and artificial intelligence initiatives but will no longer report directly to the Chief Executive Officer. The filing does not describe additional changes to his responsibilities or to other executive roles.
Intuitive Surgical Inc. reported that a senior officer sold company stock. On 12/15/2025, the SVP & Chief Mfg and Supply Chain Officer sold 464 shares of common stock at a price of $548.49 per share in an open market transaction. After this sale, the officer beneficially owned 131 shares, held directly.
The company notes that the trade was executed under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule. This plan is stated to comply with SEC Rule 10b5-1 and is scheduled to expire on February 14, 2027.
Intuitive Surgical executive Mark Brosius reported an amended insider transaction showing an open-market sale of 312 shares of Common Stock at $547.36 per share on December 12, 2025. After this sale, he directly owned 595 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that is scheduled to expire on February 14, 2027. This Form 4/A corrects the third transaction line from his Form 4 filed on December 15, 2025, which had incorrectly reported that transaction’s details, while all other information in the original filing remained accurate.
Intuitive Surgical executive Mark Brosius reported stock option exercises and share sales. As SVP & Chief Manufacturing and Supply Chain, he exercised 4,500 non-qualified stock options for common stock at an exercise price of $79.6378 per share on 12/12/2025, then sold 4,500 common shares that day at $547.36 per share.
He also sold 464 common shares on 12/15/2025 at $548.49 per share. After these transactions, he directly owned 443 shares of Intuitive Surgical common stock and held no remaining derivative securities from the reported option grant. The filing notes that the transactions were made under a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.